3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Terminated
4
Recruiting
4
Unknown
2
Not yet recruiting
2
Completed
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Conditions
Leukemia, Myeloid, Acute
28
Myelodysplastic Syndromes
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Leukemia, Lymphocytic, Chronic, B-Cell
13
Lymphoma, Non-Hodgkin
12
Lymphoma
12
Recurrence
11
Multiple Myeloma
11
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Leukemia
9
Leukemia, Biphenotypic, Acute
8
Ovarian Neoplasms
7
Neoplasms
7
Lymphoma, Mantle-Cell
7
Myeloproliferative Disorders
6
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell
6
Hodgkin Disease
6
Hematologic Neoplasms
6
Lymphoma, Follicular
5
Immunoproliferative Disorders
5
Immune System Diseases
5
Lymphoproliferative Disorders
4
Lymphoma, B-Cell, Marginal Zone
4
Lymphatic Diseases
4
Carcinoma, Non-Small-Cell Lung
4
Sarcoma
3
Mesothelioma
3
Lung Neoplasms
3
Interventions
Cyclophosphamide
10
Magnetic Resonance Spectroscopy
8
Temozolomide
6
Biopsy
6
dinutuximab
5
X-Rays
5
Topotecan
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Irinotecan
5
Etoposide
3
Colony-Stimulating Factors
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
sargramostim
2
pembrolizumab
2
palbociclib
2
naxitamab
2
larotrectinib
2
ivosidenib
2
fludarabine phosphate
2
fludarabine
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
Lenalidomide
2
Isotretinoin
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neuroblastoma
×
fludarabine
×
Clear all
NCT01953900
2026-04-22
VEGAS
Baylor College of Medicine
Phase 1
Active not recruiting
26 enrolled
NCT01822652
2026-04-06
GRAIN
Baylor College of Medicine
Phase 1
Active not recruiting
11 enrolled